Alto Neuroscience (NYSE:ANRO) Stock Price Up 6.6% – What’s Next?

Alto Neuroscience, Inc. (NYSE:ANRO) traded up 6.6% during trading on Tuesday . The company traded as high as $19.68 and last traded at $19.4420. 290,064 shares changed hands during mid-day trading, an increase of 2% from the average session volume of 283,774 shares. The stock had previously closed at $18.24.

Wall Street Analyst Weigh In

Several research analysts have commented on ANRO shares. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Chardan Capital reiterated a “buy” rating and set a $30.00 target price on shares of Alto Neuroscience in a report on Wednesday, April 22nd. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Alto Neuroscience in a research note on Wednesday, May 27th. Wedbush upped their target price on Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Finally, Wolfe Research assumed coverage on Alto Neuroscience in a research note on Friday, May 22nd. They set an “outperform” rating for the company. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Stock Performance

The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $729.35 million, a price-to-earnings ratio of -8.59 and a beta of 1.24. The business has a 50-day moving average price of $22.77 and a 200-day moving average price of $19.36.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, sell-side analysts forecast that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Invesco Ltd. purchased a new position in Alto Neuroscience during the 1st quarter worth approximately $67,000. AQR Capital Management LLC acquired a new stake in shares of Alto Neuroscience in the first quarter worth $52,000. Marshall Wace LLP raised its holdings in shares of Alto Neuroscience by 9.9% during the second quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after purchasing an additional 84,417 shares during the last quarter. Jane Street Group LLC purchased a new stake in Alto Neuroscience in the second quarter valued at $240,000. Finally, Bridgeway Capital Management LLC lifted its holdings in shares of Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after buying an additional 25,000 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.